These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25409784)

  • 1. Behavioral phenotypes for negative symptoms in animal models of schizophrenia.
    Miyamoto Y; Nitta A
    J Pharmacol Sci; 2014; 126(4):310-20. PubMed ID: 25409784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCP-induced deficits in murine nest building activity: employment of an ethological rodent behavior to mimic negative-like symptoms of schizophrenia.
    Pedersen CS; Sørensen DB; Parachikova AI; Plath N
    Behav Brain Res; 2014 Oct; 273():63-72. PubMed ID: 25064467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
    Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
    Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral animal models of antipsychotic drug actions.
    Peleg-Raibstein D; Feldon J; Meyer U
    Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis.
    Enomoto T; Noda Y; Nabeshima T
    Methods Find Exp Clin Pharmacol; 2007 May; 29(4):291-301. PubMed ID: 17609743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment.
    Millan MJ; Fone K; Steckler T; Horan WP
    Eur Neuropsychopharmacol; 2014 May; 24(5):645-92. PubMed ID: 24820238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating negative-symptom-like behavioural changes in developmental models of schizophrenia.
    Moser P
    Eur Neuropsychopharmacol; 2014 May; 24(5):774-87. PubMed ID: 24332891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence of the deficit form in refractory schizophrenia].
    Samuelian JC
    Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.
    Carbon M; Correll CU
    CNS Spectr; 2014 Dec; 19 Suppl 1():38-52; quiz 35-7, 53. PubMed ID: 25403863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.
    Wilson CA; Koenig JI
    Eur Neuropsychopharmacol; 2014 May; 24(5):759-73. PubMed ID: 24342774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anhedonia, self-experience in schizophrenia, and implications for treatment.
    Juckel G; Sass L; Heinz A
    Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S176-80. PubMed ID: 14677076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
    Bosia M; Pigoni A; Cavallaro R
    Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetically modified mice related to schizophrenia and other psychoses: seeking phenotypic insights into the pathobiology and treatment of negative symptoms.
    O'Tuathaigh CM; Desbonnet L; Waddington JL
    Eur Neuropsychopharmacol; 2014 May; 24(5):800-21. PubMed ID: 24290531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules.
    Mouri A; Nagai T; Ibi D; Yamada K
    Neurobiol Dis; 2013 May; 53():61-74. PubMed ID: 23142533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pick Your Model Wisely: Understanding the Negative Symptoms of Schizophrenia in Rodent Models.
    Yohn SE; Conn PJ
    ACS Chem Neurosci; 2019 Jan; 10(1):33-35. PubMed ID: 30346132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting negative symptoms in schizophrenia: opportunities for translation into new treatments.
    Foussias G; Siddiqui I; Fervaha G; Agid O; Remington G
    J Psychopharmacol; 2015 Feb; 29(2):116-26. PubMed ID: 25516370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of biomarkers in the discovery of novel anti-schizophrenia drugs.
    Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J
    Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling schizophrenia: uncovering novel therapeutic targets.
    Desbonnet L; O'Tuathaigh CM; Waddington JL
    Expert Rev Clin Pharmacol; 2012 Nov; 5(6):667-76. PubMed ID: 23234324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.